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CJD mimics and chameleons
Simon Mead, Peter Rudge
ABSTRACT
Rapidly progressive dementia mimicking
Creutzfeldt–Jakob disease (CJD) is a relatively
rare presentation but a rewarding one to
become familiar with, as the potential diagnoses
range from the universally fatal to the completely
reversible. Patients require urgent decisions about
assessment and investigation and have quickly
evolving needs for treatments and support,
through symptom management and end-of-life
care in most cases. We have based this
pragmatic review on the experiences of a
specialist prion referral centre in the UK, which,
unsurprisingly, is strongly biased towards seeing
patients with CJD. Cases eventually proven not
to have prion disease might be described as
‘CJD-mimics’; being referred from UK
neurologists, these are the most challenging
cases. CJD in its classical presentation is very
rarely mimicked; however, it is highly
heterogeneous, and atypical forms can mimic
virtually all common neurodegenerative
syndromes. Warning features of a mimic include
generalised seizures, hyponatraemia, fever, a
facial movement disorder, a normal neurological
examination and a modestly rapid presentation.
Contrast-enhancing lesions or MRI signal
hyperintensity outside the striatum, thalamus or
cortex and a cerebrospinal fluid pleocytosis are
key investigation pointers to a CJD mimic.
INTRODUCTION
Rapidly progressive dementia (RPD) is a
clinical syndrome that is not well defined
and little studied. There are some excel-
lent and comprehensive reviews,1–3
including by Murray,4 in this journal. The
archetypal diagnosis is Creutzfeldt–Jakob
disease (CJD), and most experiences have
been reported from specialist prion
disease referral centres and from a small
number of specialist cognitive clinics.
Some have used a definition of a diag-
nosis of dementia within 1 year of
symptom onset, although this is problem-
atic, as initial symptoms are often non-
specific and merge with highly prevalent
complaints in the population; therefore,
the exact time of onset is hard to
pinpoint. Nevertheless, the concept of
RPD is sensible, as it differentiates a set
of syndromes and diagnoses that are, to a
significant degree, distinct from those
seen in the differential diagnosis of
common neurodegenerative disorders.
CJD is associated with progression from
normal function to death in under a year
in approximately 90% of patients.5
Those reporting the history of patient
with CJD witness a cognitive and neuro-
logical disorder leading to obvious
progressive changes in everyday functions
over periods of weeks or a month’s dura-
tion, rather than noticing change over 6
months to a year, which would be more
typical of a common dementia.
There are no population studies of
RPD, and the experience in prion disease
referral centres is likely to be substantially
different from the reality in primary and
secondary care centres. Referral patterns
vary considerably between countries,
based on historical factors and the serv-
ices provided by a specialist clinic. The
proportion of RPD patients eventually
diagnosed as prion disease varies in
reports from 20% to the large majority
(>80% in our case).1 6 This variation
relates to the considerable amount of
filtering done by local physicians before
patients are referred.
Undoubtedly, many patients with rapid
changes in their function and dementia
have a delirium, recognised by acute or
subacute deficits in attention; concentra-
tion and orientation; a cognitive disorder
and an explanatory toxic, metabolic or
infective physiological problem (Diag-
nostic and Statistical Manual of Mental
Disorders, Fifth edition). A key feature
here is the identification through history
taking of a pre-existing and more insidi-
ously progressive cognitive disorder.
Similarly, multiple strokes, viral encepha-
litis and brain tumours might meet our
working definition of RPD but are
readily identified at initial assessments.
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Here, we focus more on particularly difficult cases
that have made it through the filters of local physi-
cians and were therefore challenging to differentiate
from CJD.
What are the phenotypes of CJD?
Prion diseases are highly heterogeneous disorders
with distinct causes, clinical features and durations.7
Most commonly (~85% of the annual incidence), the
cause is unknown, termed ‘sporadic’ CJD. Acquired
causes are sometimes immediately obvious, such as
treatment with cadaveric pituitary-derived human
growth hormone (before 1985), or using cadaver-
derived dura mater to repair defects during neurosur-
gery (before 1992). Variant CJD, caused by the
human transmission of the cattle prion disease bovine
spongiform encephalopathy, involved much more
widespread exposure of the UK and other popula-
tions, although specific at-risk groups, such as those
patients who received a blood transfusion derived
from a donor who later developed variant CJD, are
identifiable. These individuals may have been notified
of their increased risk status. The recognition of
genetic causes may be prompted by evidence of a
familial disorder; however, family history is often
negative in definite cases, because for example,
several causal genetic mutations typically manifest in
old age and are partially penetrant. The range of clin-
ical phenotypes of inherited prion disease extends far
beyond RPD, and investigation results are much less
specific than for CJD; consequently, our practice for
all undiagnosed cases that we see is to screen the only
gene that contains mutations that cause inherited
prion disease, the prion protein gene (PRNP).
In advanced stages, all prion diseases look very
similar: the patients have akinetic mutism. They lie
still in a hospital bed, often have eyes open but not
tracking a face moving across the visual field,
have occasional spontaneous or startle-related myoc-
lonus, are incontinent and silent or make only
incomprehensible noises. If swallowing is retained and
depending on other aspects of supportive care,
patients can survive in this state for several weeks,
even years, with tube feeding. In sporadic CJD,
patients deteriorate to this state as rapidly as in a few
weeks in the fastest cases or over a year in 10%.8 In
the vast majority of cases, patients are admitted for
urgent inpatient assessment following the first inter-
view in the hospital, and investigations leading to
diagnosis are organised in a single hospital stay. Many
patients are discharged from this first hospital stay
into 24-hour care or a hospice.
The first symptoms of sporadic CJD are usually
non-specific: headache, malaise, cough, dizziness
and change in personality, mood or memory. The first
more CJD-specific symptoms are diverse and lead to
distinct initial differentials (figure 1). In half of
the cases, the more typical picture of CJD is present
on exploring the history further or reveals itself
during examination or shortly after an initial assess-
ment. In its classical presentation (figure 1), the
clinical syndrome of CJD comprises an RPD (wide-
spread cognitive domains: memory, dysexecutive,
behaviour disturbance, abnormalities of calculation
and spelling and dysphasia9) associated with cerebellar
ataxia, myoclonus, pyramidal and extrapyramidal
motor signs and often evidence of a disorder of
higher visual functions. Aside from rapid forms of
common neurodegenerative diseases, the main differ-
entials are limbic, corticosteroid-responsive or
infective encephalitis, paraneoplastic conditions,
Wernicke’s encephalopathy, neurosarcoidosis, hypo-
thyroidism, non-convulsive status epilepticus, hypoxic
encephalopathy, a toxic/metabolic syndrome or a
functional disorder.
Atypical presentations cause more difficulty,
including pure cognitive presentations (~15%) that
might be mistaken for rapid forms of Alzheimer’s
disease, frontotemporal dementia or dementia with
Lewy bodies; ataxic presentations (~10%) are often
associated with acquired CJD and might be mistaken
for disorders of the cerebellum and its brainstem
connections, including vascular, neoplastic, paraneo-
plastic or inflammatory conditions. The visual
presentation or Heidenhain variant (~5%) is particu-
larly distressing for patients with hemianopia or
scotoma, misperceptions, hallucinations, distortions
and palinopsia. Progression tends to be rapid, even
relative to other presentations of CJD. The condition
often presents to ophthalmologists or optometrists
as an ocular disorder, for example, suspected cata-
ract.10 Psychiatric presentations (~5%) also occur;
thus, in variant CJD, depression and personality
change are common early in the evolution of the
disease, while paranoia, visual hallucinations and
aggression occasionally occur during the initial phase
of the disease in sporadic CJD, suggesting a primary
psychiatric diagnosis of psychosis or depression.11
Very rare presentations include those that mimic a
stroke (~2%) or corticobasal syndrome (~2%). The
thalamic presentation (~2%) includes sleep
disturbance and distal pain and may include abnor-
malities of the autonomic nervous system:
palpitations, temperature dysregulation, hypertension
or postural hypotension. This presentation is well
known as fatal familial insomnia and is typically asso-
ciated with the inherited prion disease caused by the
D178N missense mutation in PRNP, usually linked to
a methionine allele at polymorphic codon 129;
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however, there have been cases without this or any
gene mutation.
While we list the obvious conditions that a neurolo-
gist would consider after an initial assessment, it is
usually clear that the patient warrants urgent and
comprehensive investigation. At an initial assessment,
the rapidity of progression may not be evident, either
because there is no witness account available or
because comorbidities or prodromal symptoms
obscure the underlying disease. Some interventions
are therefore indicated immediately while waiting for
initial test results. Suspect cases of viral encephalitis
should be treated with intravenous acyclovir. Cases
associated with weight loss, alcohol excess or other
evidence of malnutrition should be treated with intra-
venous vitamins. In all patients, we recommend
a blood screen, including routine haematology,
biochemistry, thyroid function, vitamin B12, serology
for neurosyphilis, paraneoplastic antibodies and
serology for limbic encephalitis; MR scan of brain
(dementia protocol), including axial diffusion-
weighted imaging and fluid-attenuated inversion
recovery (FLAIR); electroencephalograph (EEG) and
cerebrospinal fluid (CSF) examination for basic
constituents, 14-3-3 protein, S100b, abeta and tau
proteins, and the real-time quaking-induced conver-
sion assay (RT-QUIC) (table 1).
Investigation features of CJD
Imaging
MR imaging of brain is an extremely useful investiga-
tion in CJD, because it is readily available at short
notice and non-invasive.12 Classical abnormalities
are high signal on diffusion-weighted imaging or
FLAIR in the striatum, cerebral cortex and/or thal-
amus (figure 2). Changes at these three sites may
occur in isolation or combination. Cortical signal
change is often patchy and extensive but should
involve more than one cortical region and areas that
are not vulnerable to artefactual signal change (eg, the
frontal pole) and should not enhance or show mass
effect. Thalamic signal change may be diffuse or have
emphasis in dorsal and medial aspects but should not
be of greater signal intensity than in the striatum in
sporadic CJD. Most units report a sensitivity of
MRI>90% in the diagnosis of sporadic CJD. In grey
matter, CJD is associated with small vacuoles in
neuronal cell bodies, axons or dendrites, which are
most probably the pathological substrate for imaging
abnormalities. Often, cortical signal change correlates
Figure 1 Creutzfeldt-Jakob disease (CJD) clinical features and progression. The boxes describe clinical variants of CJD. The width of
each arrow relates to the proportion of cases with the presentation. Patients with CJD become more similar over time, and almost all
enter a phase of ‘akinetic mutism’ before death.
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with clinical features, for example, contralateral in the
frontal lobe in patients with hemiparesis or occipital
cortex signal change in the visual variant of CJD.
Post-gadolinium imaging can help identify blood–
brain barrier breakdown in lymphoma and neuroin-
flammatory conditions, which is not seen in CJD.
Electroencephalogram
The EEG is less useful with the availability of very
specific imaging and CSF tests. Periodic sharp wave
complexes develop in half of the patients with
sporadic CJD, particularly in the later stages. It is
most useful when showing unexpected findings that
would be unusual in CJD and provide suggestive
evidence for alternative diagnoses. These include peri-
odic lateralising epileptiform discharges in
encephalitis, frontal intermittent delta activity in
toxic–metabolic or structural abnormalities (if asym-
metrical), status epilepticus or runs of 2–3 s of
polyphasic slow/sharp waves (subacute sclerosing
panencephalitis). The extreme delta brush sign may
occur in autoimmune encephalitis.
Cerebrospinal fluid
Pleocytosis in CJD can occur but is rare. For 20 years,
the main CSF tests have been the detection of
proteins released into the spinal fluid, as the disease
process damages glia and neurones; these include 14-
3-3, S100b and neurone-specific enolase.13 Over 80%
of patients with CJD have abnormalities of these
proteins, but importantly, they are not specific to the
pathogenesis of CJD; rather, they reflect rapid tissue
damage, and therefore, may also be abnormal in many
of the mimic conditions. New CSF tests, such as the
real-time quaking-induced conversion assay (RT-
QUIC), are entering routine clinical use and initial
evidence suggests these are much more specific.14 The
RT-QUIC protocol involves disruption of prion
Table 1 Investigations/work-up
Screen in all CJD mimic patients Second-line test
Basic blood tests: routine haematology, biochemistry, calcium,
magnesium, vitamin B12, HIV serology, thyroid function, antinuclear
antibody, antineutrophil cytoplasmic antibody, inflammatory markers
Serum ammonia, drug levels (as appropriate)
Serology: Voltage-gated K-channel antibodies, NMDA-R antibodies,
TPHA (neurosyphilis)
Serology for specific infections (eg, Lyme), paraneoplastic
antibodies
Imaging: MR scan of brain, dementia protocol, including diffusion-
weighted axial images and post-gadolinium imaging for lymphoma/
inflammatory CNS conditions
Angiography (vasculitis, dural arteriovenous fistula, intravascular
lymphoma)
EEG: routine recording Electromyography and nerve conduction studies
CSF: for cells, biochemistry, oligoclonal bands, 14-3-3 protein, S100b
protein, RT-QUIC assay, amyloid beta protein (1–42), total tau
CSF serology for NMDA-R encephalitis, measles serology, PCR for
JC virus and for viruses associated with other encephalitides
PRNP: gene analysis Dementia gene panel diagnostics
Urine: test for infection Brain biopsy
CJD, Creutzfeldt–Jakob disease; CNS, central nervous system; CSF, cerebrospinal fluid; EEG, electroencephalogram; JC, John Cunnigham, NMDA-R, N-
methyl-D-aspartate; PRNP, prion protein gene; RT-QUIC, real-time quaking-induced conversion assay.
Figure 2 Typical MRI features of Creutzfeldt-Jakob
disease (CJD). (A and B) Sporadic CJD showing typical basal
ganglia signal return on fluid-attenuated inversion
recovery (FLAIR) (A), which is more obvious on diffusion-
weighted sequences (B). (C) Diffusion-weighted imaging
sequence showing striking cortical ribboning with normal basal
ganglia in sporadic CJD. (D) Variant CJD showing pulvinar sign
on the FLAIR sequence.
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protein aggregates in a test sample by rounds of
shaking, followed by incubation in an excess of
recombinant prion protein and induction of recombi-
nant prion protein misfolding, detected by an increase
thioflavin T fluorescence through the protocol (hence
real time). CSF angiotensin-converting enzyme can
help diagnose neurosarcoidosis.
Prion protein gene sequencing
Prion protein gene sequencing should, in our opinion,
be routinely considered in all cases. The phenotypic
spectrum of inherited prion disease is more diverse
than CJD, and family history is often absent due to
old-age presentations/partial penetrance. Most
patients with CJD are homozygous at the common
polymorphism at codon 129 of the gene. The fastest
declining patients with CJD are typically methionine
homozygous at this site, whereas the more slowly
changing patients are usually methionine–valine
heterozygous. While this is a powerful effect, ruling
out inherited prion disease is the most important
purpose for gene sequencing. Gene testing has impli-
cations for blood relatives, who must be involved in
the decision to proceed.
Other tissues and biofluids
Tonsillar biopsy or a blood test (the Direct Detection
Assay, from the National Prion Clinic) can be used in
the diagnosis of variant CJD but has no use in the
sporadic form. Prion protein amplification or capture
diagnostic technologies may be used in the future, with
material from olfactory brushings or using urine or
blood, but for the time being, these tools are in research
development for sporadic CJD.15 16 Brain biopsy is
seldom used to make a diagnosis of CJD, because it is
reserved for circumstances when a reversible diagnosis
seems possible, in particular where a specific lesion is to
be targeted. It is essential to take prion precautions
before neurosurgery in suspect cases. For more detailed
guidance, see https://www.gov.uk/government/publica-
tions/guidance-from-the-acdp-tse-risk-management-
subgroup-formerly-tse-working-group.
Mimics of CJD after initial investigation
Once initial investigations are done, patients
who cause ongoing difficulty usually have abnormality
of at least one of the key initial tests. Most frequently,
this is a positive 14-3-3 protein in CSF.
Common neurodegenerative disorders
In over half of the mimics that the National Prion
Clinic sees, the eventual diagnosis is another neurode-
generative disease. These conditions are much more
prevalent than CJD and are also heterogeneous, with
confusion only likely to occur with the very most
rapidly progressing end of the spectrum of Alzheimer’s
disease or dementia with Lewy bodies. Comorbidities,
such as infection, leading to delirium, or drug changes
are often a factor. Key features enabling recognition
here are evidence from the witness account of pre-
existing symptoms before the acute or subacute presen-
tation. MR imaging evidence of focal or generalised
atrophy or CSF abnormality of abeta or tau proteins
are also instructive. The diagnosis becomes clear when
patients stabilise or improve, which hardly ever
happens in patients with CJD despite treatment of
intercurrent infection. Vascular disease in the striatum,
cortex or thalamus can also contribute to diagnostic
confusion, because at first glance, this might suggest
prion disease. Myoclonus, ataxia and motor signs can
develop in common neurodegenerative diseases and
can worsen with drug treatments, for example, tricy-
clics and myoclonus, antiepileptic drugs and ataxia,
neuroleptics and dementia with Lewy bodies.
Although there are no specific disease-modifying
therapies, accurate diagnosis of CJD can lead to mean-
ingful management decisions about symptomatic
therapies and choices for the patient and carers. All
neurodegenerative disorders have Mendelian genetic
causes, which (eg, in the case of C9orf72 expansion)
can be associated with rapid progression and motor
signs that bring CJD into the differential. The avail-
ability of gene panel diagnostics will identify an
increasing proportion of cases with a specific genetic
diagnosis.17
We are particularly interested in potentially treatable
mimics, which may be grouped into the following
categories.
Immune-mediated encephalitis
Probably, the most important CJD mimics are the
recently characterised antibody-mediated inflamma-
tory disorders of the central nervous system.18 19
While some are paraneoplastic and fluorodeoxyglucose
PET is useful in locating the underlying tumour, a
substantial proportion is not associated with antibodies
directed to a range of neuronal surface ion channels
and membrane receptors. Many cases have dramatic or
significant recovery following immune therapies.
N-methyl-D-aspartate receptor (NMDAR) antibody
encephalitis is the most commonly recognised type,
initially linked to ovarian teratoma in young women,
which remains a prompt to consider the diagnosis.
Like in patients with CJD, the history often includes a
non-specific prodromal stage, developing into behav-
ioural and psychiatric features, and early generalised
and focal seizures that would be very unusual in CJD.
Movement disorders commonly develop in CJD, but
the specific facial dyskinesia of NMDAR encephalitis
would prioritise the disorder. Other flags for the
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disorder are a CSF pleocytosis, CSF oligoclonal
bands, and MR imaging findings (Table 3). These can
include T2 or FLAIR hyperintensity of the striatum,
thalamus and cortex as might occur in CJD (figure 3)
but more typically include abnormalities in other
areas, particularly the mesial temporal lobe and
hippocampus, and also the brainstem, cerebellum and
white matter, often with enhancement or mass effect
from inflammation. We recommend testing at least
serum in all patients suspected to have CJD and CSF
in patients with flags for the disorder.
Voltage-gated potassium channel (VGKC) complex
antibody encephalitis is similarly a crucial mimic of
CJD to exclude. Importantly, we now know that patho-
genic antibodies are directed at individual members of
the VGKC multiprotein complex, for example, LGI1,
which may give more specific tests. While associated
with a wide range of clinical syndromes, the most
commonly confused picture with CJD is one that may
include both peripheral manifestations—neuromyo-
tonia, a twitching or stiffness related to spontaneous
motor nerve excitability, and autonomic disturbances—
and central manifestations, such as brief and frequent
seizures affecting ipsilateral face and arm (termed
‘faciobrachial dystonic’), insomnia, memory
impairment and behavioural disturbances or more
florid manifestations of an encephalitis. Investigation
prompts to the diagnosis include hyponatraemia and
MR imaging abnormalities of the mesial temporal lobe
and hippocampus, which can also involve the basal
ganglia (figure 3).
Other protein targets in immune-mediated encephalitis
are proliferating and include glutamic acid decarbox-
ylase,which can be associated with limbic encephalitis or
cerebellar ataxia; AMPA receptor antibody encephalitis,
often associated with tumours, psychosis and limbic
encephalitis;GABAA or GABABR antibody limbic enceph-
alitis; glycine receptor antibodies, which may occur in
progressive encephalopathy with generalised stiffness,
autonomic abnormalities and myoclonus (progressive
encephalomyelitis with rigidity and myoclonus);
and metabotropic glutamate receptor antibodies, which
have been reported in subacute cerebellar degeneration.
Hashimoto’s encephalitis is commonly referred to as
a key differential of CJD, but we have never seen this
at the Prion Clinic. Testing of thyroid function and
antithyroperoxidase antibodies is simple to do,
although many patients reported to have the disorder
are euthyroid. The pathogenesis of this disorder and
its distinction from other immune-mediated encepha-
litides is unclear.
Infections
Progressive multifocal encephalopathy is an opportu-
nistic brain infection associated with the polyoma JC
virus infection, almost exclusively in immunocompro-
mised people. There is usually a history of
immunosuppressive drug use, HIV, Hodgkin’s
lymphoma or chronic lymphocytic leukaemia. The
condition is hard to link to a specific symptom,
although it is mistaken for CJD because of rapid
progression of disability and its common involvement
of visual pathways or cerebellar ataxia. As for enceph-
alitis, the occurrence of generalised seizures in half of
the cases would be unusual for CJD. Imaging features
should be distinct from CJD, with a propensity for
parieto-occipital demyelinating lesions at the junction
of grey and white matter, less commonly seen in the
corpus callosum, thalamus and basal ganglia. CSF is
used to confirm diagnosis with PCR for JC virus, but
Figure 3 MR scan of brain in four patients presenting as
mimics of prion disease. (A) C9orf72 mutation showing severe
generalised atrophy with no parenchymal abnormal signal.
Severe atrophy does occur late in some cases of Creutzfeldt-
Jakob disease (CJD), but usually diffusion-weighted sequences
reveal restricted diffusion. (B) B-cell lymphoma confined at
the time of presentation to the brain. Note the extensive white-
matter signal change with the normal cortex. Occasionally, the
leukoencephalopathic form of CJD has white-matter signal
alteration, but this is associated with grey matter destruction.
(C) N-methyl-D-aspartate antibody encephalitis with MR
imaging showing the pulvinar sign. This sign develops in most
cases of variant CJD and has rarely been described with other
pathologies. (D) Voltage-gated potassium channel (Casp-1)
antibody encephalitis showing unilateral basal ganglia high
signal on diffusion-weighted imaging but not on the apparent
diffusion coefficient map (scan not shown). Note that the
swelling of the caudate is a feature that does not occur in CJD.
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a pleocytosis often occurs and would be another
feature against a diagnosis of CJD.
Subacute sclerosing panencephalitis is a rare late
complication of measles infection in early childhood.
The clinical picture can look quite similar to CJD,
with early lethargy and behavioural change followed
by a ‘hung-up’ type of myoclonus, seizures, cognitive
impairment, later motor signs and reduced level of
consciousness. The diagnosis should be considered in
children or young adults and may be prompted by
EEG findings of bilaterally synchronous and repetitive
sharp complexes lasting a few seconds. CSF antibody
titres for measles are diagnostic.
Other viral encephalitides usually present acutely
and are immediately recognised by general features
such as fever and raised inflammatory markers in
serum and CSF, along with more specific features of
brain infection like seizures, meningism and coma.
Occasionally, its more subacute presentations may
cause some confusion with CJD.
A wide range of bacterial, fungal and parasitic infec-
tions that can cause an RPD should be on a reference
checklist (table 2) but have not caused diagnostic
confusion with CJD at our clinic.
Toxic–metabolic syndromes
Most of these syndromes are picked up in the initial
laboratory testing, which should include basic serum
biochemistry, calcium, magnesium, glucose and
thyroid function. It is important to emphasise the
importance of Wernicke’s encephalopathy, an acute
neurological disorder, precipitated by thiamine defi-
ciency, characterised by the clinical triad of
ophthalmoplegia, ataxia and confusion, which should
be treated with urgent intravenous B vitamin replace-
ment. Imaging features may partially overlap those of
CJD. The encephalopathy associated with hepatic
failure has mimicked CJD on a couple of occasions at
our clinic, with the associated negative myoclonus (a
sudden loss of muscle tone) in comatose patients
mimicking the end stages of CJD. The detection of
hyperammoninaemia either as part of rare genetic
urea cycle disorders, drug therapy or liver failure can
be crucial in the diagnosis of a toxic encephalopathy.
Table 2 Differential diagnosis checklist
Common disorders with rare presentation
that mimic CJD
Rare but potentially treatable/reversible mimics Rare and untreatable mimics
of CJD
Rapidly progressive forms of common
neurodegenerative diseases
Limbic and other immune-mediated encephalitis Unusual infections: subacute
sclerosing panencephalitis
Delirium and pre-existing dementia Metabolic and endocrine conditions
(hyperammonaemia, electrolyte disturbance,
hypoglycaemia/hyperglycaemia, uraemia)
Mitochondrial cytopathy
Viral encephalitis Primary CNS vasculitis Diffuse neoplastic disease (eg,
carcinomatous meningitis,
gliomatosis cerebri)
Hepatic failure and encephalopathy Neurosarcoidosis
Cerebrovascular disease (single or multiple
strokes) or hypoxic encephalopathy
Primary CNS and intravascular lymphoma
Wernicke’s encephalopathy and related
manifestations of alcohol-related dementia (eg,
extrapontine myelinolysis)
Unusual infections: progressive multifocal
leukoencephalopathy, fungal encephalitis, Lyme disease,
Whipple’s disease, neurosyphilis
Thyroid dysfunction Large dural arteriovenous fistula
HIV-related dementia
Subacute combined degeneration
CNS manifestations of autoimmune disorders (eg, lupus,
sarcoidosis)
Heavy metal toxicity (eg, lithium, mercury)
Toxicity related to medications (eg, lithium, valproate)
Non-convulsive status epilepticus
Psychiatric conditions: functional disorders, catatonia,
depression
CJD, Creutzfeldt–Jakob disease; CNS, central nervous system.
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In addition, a high signal in the lentiform nucleus on
T1 MRI sequences due to manganese deposition
strongly suggests hepatic encephalopathy.
Neoplastic and paraneoplastic conditions (other than limbic encephalitis)
The conditions hardest to distinguish are those with no
or only subtle mass lesions on MRI. Typically, these
include primary CNS lymphoma, carcinomatosis and
intravascular lymphoma. In these cases, the imaging
findings are usually the crucial diagnostic. Primary
CNS lymphoma is usually associated with enhancing
lesions in contact with CSF. Large-volume CSF
sampling for cell analysis before a trial of corticoste-
roids may avoid brain biopsy. Serum tumour markers
and whole-body imaging may also help. Intravascular
(B-cell) lymphoma is a rare and notoriously difficult
diagnosis. It leads to rapid cognitive decline, seizures,
upper motor neurone signs and peripheral signs such as
those of a neuropathy. Imaging findings overlap those
of primary CNS vasculitis.
Vascular
We have seen cases of large vessel stroke, dural arte-
riovenous fistula, posterior reversible encephalopathy
syndrome and primary CNS vasculitis as mimics of
CJD. In each case, the MR imaging review was the
main indicator of the diagnosis.
Mimics relevant to other types of prion disease
Genetic and iatrogenic forms of prion disease often
do not progress as rapidly as CJD and therefore
have distinct differentials. A common phenotype of
several inherited prion disease mutations is a
modestly progressive (over the years) cerebellar
ataxia, often with a distal leg sensory disturbance,
absent ankle jerks and extensor plantar responses.
Iatrogenic CJD also commonly presents with ataxia
and normal or near-normal cognitive function and is
slightly slower in progression than typical sporadic
CJD. Other forms of inherited prion disease have
pure cognitive presentations, often with behavioural
disturbance and are mistaken for the frontal variant
of Alzheimer’s disease, Huntington’s disease (as
there is an autosomal dominant family history) or
frontotemporal dementia.
Conclusions and possible developments
RPD mimicking CJD is rare but requires urgent inves-
tigation and can be difficult to diagnose. This can be
more rewarding than the investigation of insidiously
progressing cognitive dysfunction, as there is a wide
range of potentially treatable disorders. Specialist
services for prion disease, including the NHS National
Prion Clinic at the National Hospital for Neurology
and Neurosurgery (University College London Hospi-
tals NHS Trust) and the National CJD Research and
Surveillance Unit at Edinburgh University, are here to
help for assessment, to advise about local
investigation and to provide access to molecular
genetics and other diagnostics, follow-up and
supportive care. We like to hear about cases as early
as possible, certainly immediately after a scan showing
changes compatible with CJD.
With such rare disorders, clinical research can
most effectively be done when concentrated in
national centres with long-term funding and
provided alongside specialist care in partnership
with local physicians. Research is delivering mean-
ingful improvements, with specific blood and CSF
prion disease diagnostics moving from the laboratory
to clinical use in the last 5 years. It is hard to
predict when we shall see any meaningful treat-
ments, but this is certainly a major focus of activity
at the moment. Progress in this area will not be
Table 3 Red flags: clinical features that might indicate a CJD mimic
Feature Indicates
Fever Infections, lymphoma
Seizures Implies less likely to be CJD, infective and immune encephalitis, neoplasia, many
other mimics
Hyponatraemia VGKC encephalitis
Facial movement disorder NMDA-R encephalitis, CNS Whipple’s disease
Modest progression Implies less likely to be CJD, more likely to be a common neurodegenerative
disorder
CSF pleocytosis Infections, lymphoma, inflammatory, neoplastic
Contrast-enhancing lesions Infections, lymphoma, inflammatory, neoplastic
MRI hyperintensities on T2-weighted imaging outside the
striatum, thalamus and cortex
Vascular diseases, lymphoma, progressive multifocal leukoencephalopathy,
encephalitis, extrapontine myelinolysis, others
CJD, Creutzfeldt–Jakob disease; CNS, central nervous system; CSF, cerebrospinal fluid; NMDA-R, N-methyl-D-aspartate; VGKC, voltage-gated potassium
channel.
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possible without the continued referral and support
of UK neurologists.
Key points
" Creutzfeldt–Jakob disease (CJD) is a rapidly progressive and
highly heterogeneous condition that readily mimics a wide
range of potentially reversible or treatable disorders.
" Highly sensitive and specific tests are available for CJD
diagnosis, particularly diffusion-weighted MR imaging and
cerebrospinal fluid (CSF) analysis using the real-time
quaking-induced conversion assay; while the clinical
syndrome can be mimicked, investigations should rapidly
resolve any confusion.
" Investigations are not as helpful for genetic forms of prion
disease—clinicians should have a low threshold for ruling
out this possibility by a gene test.
" Be concerned about a diagnosis of CJD in the presence of
unexplained fever, generalised seizures, hyponatraemia, a
facial movement disorder, modest rates of progression (clin-
ical duration >1 year), a CSF pleocytosis, contrast-enhancing
MR lesions and white-matter lesions outside the striatum,
thalamus and cortex.
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